Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
50mg |
|
||
Other Sizes |
|
ln Vitro |
PF-4191834 (PF-04191834) prevents the synthesis of 5-LOX products 5-HETE, 5-oxo-ETE, LTB4, and LTE4 at concentrations up to 30 μM, but does not prevent the synthesis of 5-LOX products at estimated IC50 values between 100 and 190 nM. With an IC50 value of 130 nM and an IC80 value of 370 nM, PF-4191834 (PF-04191834) strongly inhibits COX-1/2 enzymes or 12- or 15-LOX enzymes[1]. It also exerts concentration-regulated inhibition of human 5-LOX.
|
---|---|
References | |
Additional Infomation |
PF-4191834 has been investigated for the basic science of Asthma.
|
Molecular Formula |
C22H23N3O2S
|
---|---|
Molecular Weight |
393.51
|
Exact Mass |
393.151
|
CAS # |
1029317-21-2
|
PubChem CID |
24986635
|
Appearance |
White to yellow solid powder
|
LogP |
4.921
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
4
|
Rotatable Bond Count |
5
|
Heavy Atom Count |
28
|
Complexity |
532
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
DVNQWYLVSNPCJZ-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C22H23N3O2S/c1-25-20(9-12-24-25)16-5-7-18(8-6-16)28-19-4-2-3-17(15-19)22(21(23)26)10-13-27-14-11-22/h2-9,12,15H,10-11,13-14H2,1H3,(H2,23,26)
|
Chemical Name |
4-[3-[4-(2-methylpyrazol-3-yl)phenyl]sulfanylphenyl]oxane-4-carboxamide
|
Synonyms |
PF 04191834; PF04191834; PF-04191834
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~254.13 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.35 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5412 mL | 12.7062 mL | 25.4123 mL | |
5 mM | 0.5082 mL | 2.5412 mL | 5.0825 mL | |
10 mM | 0.2541 mL | 1.2706 mL | 2.5412 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.